FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2010769919> ?p ?o ?g. }

• W2010769919 endingPage "881" @default.
• W2010769919 startingPage "877" @default.
• W2010769919 abstract "The majority of patients with acute myeloid leukemia (AML) will require second-line chemotherapy for either relapsed or refractory disease. Currently, only allogeneic hematopoietic cell transplantation (HCT) offers a curative option in this setting and no preferred regimen has been established. The reported efficacy of second-line regimens is widely disparate, thus limiting informed clinical decision making. A retrospective review of 77 patients receiving therapy between 2001 and 2008 with relapsed, 42, and refractory, 35, AML was performed to determine overall response rate and survival following mitoxantrone (8 mg/m2/day), etoposide (100 mg/m2/day), and cytarabine (1,000 mg/m2/day) chemotherapy administered over 5 days. Among 77 patients (median age of 54 years and 64% intermediate risk karyotype) with median follow-up of 153 days, 18% achieved a complete response and 8% a morphologic leukemia-free state. Fifty-seven (74%) experienced treatment failure, 10 of whom achieved a remission after additional therapy. Median overall survival (OS) was 6.8 months. Among patients achieving a response, 50% received consolidation with allogeneic HCT, autologous HCT (5%), or consolidation chemotherapy alone (45%). A nonsignificant trend in overall response (50%, 27%, and 23.8%) and median OS (8.3, 6.8, and 4.7 months) was observed by cytogenetic stratification into favorable, intermediate, and unfavorable risk. Patients with refractory versus relapsed disease had similar overall responses (20% and 31%, P = 0.41) and median OS (5.3 and 7.6 months, P = 0.36). Despite risk stratification by the European Prognostic Index, our series demonstrates inferior rates of response and survival, illustrating the limited activity of this regimen in our cohort. Am. J. Hematol., 2010. © 2010 Wiley-Liss, Inc." @default.
• W2010769919 created "2016-06-24" @default.
• W2010769919 creator A5005810412 @default.
• W2010769919 creator A5007254355 @default.
• W2010769919 creator A5007420876 @default.
• W2010769919 creator A5032549755 @default.
• W2010769919 creator A5052061341 @default.
• W2010769919 creator A5063691844 @default.
• W2010769919 creator A5065621786 @default.
• W2010769919 creator A5074919402 @default.
• W2010769919 creator A5081118941 @default.
• W2010769919 creator A5082510058 @default.
• W2010769919 creator A5085783292 @default.
• W2010769919 creator A5090740492 @default.
• W2010769919 date "2010-09-24" @default.
• W2010769919 modified "2023-10-15" @default.
• W2010769919 title "Second-line mitoxantrone, etoposide, and cytarabine for acute myeloid leukemia: A single-center experience" @default.
• W2010769919 cites W1586763410 @default.
• W2010769919 cites W1804439365 @default.
• W2010769919 cites W1861929829 @default.
• W2010769919 cites W1870350942 @default.
• W2010769919 cites W1894000260 @default.
• W2010769919 cites W1965889017 @default.
• W2010769919 cites W1983425335 @default.
• W2010769919 cites W2016937505 @default.
• W2010769919 cites W2097192169 @default.
• W2010769919 cites W2106742754 @default.
• W2010769919 cites W2116858301 @default.
• W2010769919 cites W2121190158 @default.
• W2010769919 cites W2127865783 @default.
• W2010769919 cites W2159507916 @default.
• W2010769919 cites W2163123363 @default.
• W2010769919 cites W2169617123 @default.
• W2010769919 cites W24057889 @default.
• W2010769919 cites W4211073672 @default.
• W2010769919 cites W4237543851 @default.
• W2010769919 cites W4239564692 @default.
• W2010769919 cites W4376595466 @default.
• W2010769919 doi "https://doi.org/10.1002/ajh.21857" @default.
• W2010769919 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20872554" @default.
• W2010769919 hasPublicationYear "2010" @default.
• W2010769919 type Work @default.
• W2010769919 sameAs 2010769919 @default.
• W2010769919 citedByCount "36" @default.
• W2010769919 countsByYear W20107699192012 @default.
• W2010769919 countsByYear W20107699192013 @default.
• W2010769919 countsByYear W20107699192014 @default.
• W2010769919 countsByYear W20107699192015 @default.
• W2010769919 countsByYear W20107699192016 @default.
• W2010769919 countsByYear W20107699192017 @default.
• W2010769919 countsByYear W20107699192018 @default.
• W2010769919 countsByYear W20107699192019 @default.
• W2010769919 countsByYear W20107699192020 @default.
• W2010769919 countsByYear W20107699192021 @default.
• W2010769919 countsByYear W20107699192023 @default.
• W2010769919 crossrefType "journal-article" @default.
• W2010769919 hasAuthorship W2010769919A5005810412 @default.
• W2010769919 hasAuthorship W2010769919A5007254355 @default.
• W2010769919 hasAuthorship W2010769919A5007420876 @default.
• W2010769919 hasAuthorship W2010769919A5032549755 @default.
• W2010769919 hasAuthorship W2010769919A5052061341 @default.
• W2010769919 hasAuthorship W2010769919A5063691844 @default.
• W2010769919 hasAuthorship W2010769919A5065621786 @default.
• W2010769919 hasAuthorship W2010769919A5074919402 @default.
• W2010769919 hasAuthorship W2010769919A5081118941 @default.
• W2010769919 hasAuthorship W2010769919A5082510058 @default.
• W2010769919 hasAuthorship W2010769919A5085783292 @default.
• W2010769919 hasAuthorship W2010769919A5090740492 @default.
• W2010769919 hasBestOaLocation W20107699191 @default.
• W2010769919 hasConcept C126322002 @default.
• W2010769919 hasConcept C141071460 @default.
• W2010769919 hasConcept C143998085 @default.
• W2010769919 hasConcept C2776694085 @default.
• W2010769919 hasConcept C2778041864 @default.
• W2010769919 hasConcept C2778119113 @default.
• W2010769919 hasConcept C2778336483 @default.
• W2010769919 hasConcept C2778461978 @default.
• W2010769919 hasConcept C2778729363 @default.
• W2010769919 hasConcept C2780775027 @default.
• W2010769919 hasConcept C2780923524 @default.
• W2010769919 hasConcept C2781413609 @default.
• W2010769919 hasConcept C2911091166 @default.
• W2010769919 hasConcept C71924100 @default.
• W2010769919 hasConcept C90924648 @default.
• W2010769919 hasConceptScore W2010769919C126322002 @default.
• W2010769919 hasConceptScore W2010769919C141071460 @default.
• W2010769919 hasConceptScore W2010769919C143998085 @default.
• W2010769919 hasConceptScore W2010769919C2776694085 @default.
• W2010769919 hasConceptScore W2010769919C2778041864 @default.
• W2010769919 hasConceptScore W2010769919C2778119113 @default.
• W2010769919 hasConceptScore W2010769919C2778336483 @default.
• W2010769919 hasConceptScore W2010769919C2778461978 @default.
• W2010769919 hasConceptScore W2010769919C2778729363 @default.
• W2010769919 hasConceptScore W2010769919C2780775027 @default.
• W2010769919 hasConceptScore W2010769919C2780923524 @default.
• W2010769919 hasConceptScore W2010769919C2781413609 @default.
• W2010769919 hasConceptScore W2010769919C2911091166 @default.
• W2010769919 hasConceptScore W2010769919C71924100 @default.

• next